Study design: Prospective cohort study. Objectives: To investigate the relationship between 51 chromium-ethylene-diamine-tetra-acetate ( 51 Cr-EDTA) clearance, serum cystatin C (CysC), serum creatinine, creatinine clearance and estimated glomerular filtration rate (eGFR MDRD , MDRD stands for modification of diet in renal disease) based on the serum creatinine in patients with complete or incomplete spinal cord injury (SCI) and to develop and evaluate a GFR-estimating equation using serum CysC. Settings: Spinal Cord Injury Unit, Viborg Regional Hospital, Viborg, Denmark. Methods: Ninety-eight men and 47 women with SCI were included in the study. Serum CysC levels were measured by an automated particle-enhanced nephelometric immunoassay, serum and urine creatinine levels were measured by an enzymatic method traceable to the IDMS creatinine reference method, and 51 Cr-EDTA clearance was measured by a multiple plasma sample method. Results: The area under the curves (AUCs) in the non-parametric receiver operating characteristics (ROC) plots for serum CysC were compared with serum creatinine and to eGFR MDRD and revealed a significant difference (P-valueo0.05) for all SCI patients. There was no significant difference between the AUC for serum CysC compared with the AUC for creatinine clearance. GFR (ml min À1 per 1.73 m 2 ) can be calculated from serum CysC values (mg l À1 ) using the equation eGFR CysC ¼ 212 Á exp(0.914 Á CysC). The model accurately predicted the GFR of 88% of patients within ±30% of the measured GFR, and it was able to predict the GFR of 50% of patients within ± 10% of the measured GFR. Conclusion: In patients with SCI, GFR can be estimated independent of age, sex and muscle mass by a newly developed equation based on a single serum CysC value.
INTRODUCTION
Patients with spinal cord injuries (SCIs) are at increased risk of developing renal insufficiency, and these patient needs to have their renal function examined on a regular basis. 1 The glomerular filtration rate (GFR) is generally considered the best measure of renal function. 2 Determining the GFR requires the use of invasive techniques to measure the plasma clearance rate of an injected substance exclusively excreted via glomerular filtration, for example, inulin, 51 chromiumethylene-diamine-tetra-acetate ( 51 Cr-EDTA), 99m Tc-DTPA, 125 Iiothalamate or iohexol. 2 All of these procedures are laboratoryintensive, time consuming, expensive, and not suitable for routine use.
The measurements of serum creatinine and creatinine clearance are used as indirect markers of the GFR. 2, 3 However, the concentration of serum creatinine is not an ideal indicator of GFR, and glomerular filtration is only one of the parameters that determines the serum concentration of creatinine. Renal handling and metabolism, food intake and methodological interference may influence the concentration of serum creatinine. 3 Creatinine correlates with muscle mass, and patients with spinal cord injuries exhibit rapidly decreasing muscle mass after the injury. Accurately measuring creatinine clearance involves a 24-h urine collection, which is often difficult and time consuming for patients to perform. 4 In patients with SCIs, urine collection is particularly difficult and often inaccurate, and creatinine clearance is encumbered with some uncertainties. 5, 6 There have been several attempts to construct equations to predict GFR based on the serum creatinine and additional parameters. 7 For adults, the most accepted and widely used GFR prediction equation is that proposed by the modification of diet in renal disease (MDRD), which reports relative GFR values in ml min À1 per 1.73 m 2 . 2, 8 Cystatin C (CysC) is a new promising marker of GFR. 9, 10 CysC is a non-glycosylated, low molecular weight protein (M r ¼ 13 359 Da). It is produced by all nucleated cells at a constant rate, freely filtered in the glomeruli and reabsorbed and catabolised in the proximal tubular cells. 9, 10 The characteristics of CysC indicate that its serum concentration is largely determined by GFR, thus making CysC an endogenous indicator of GFR. CysC levels are independent of gender, age (41 year) and muscle mass. 9, 10 The aim of this prospective study was to investigate the relationship between 51 Cr-EDTA clearance (gold standard for GFR), serum CysC, serum creatinine, creatinine clearance and eGFR MDRD in a large cohort of patients with complete and incomplete spinal cord injuries and to develop and evaluate a GFR-estimating equation using serum CysC.
MATERIALS AND METHODS Patients
One hundred and forty-five patients (98 men and 47 women) between the ages of 11.3 and 82.4 years with SCIs classified as the American Spinal Injury Association (ASIA) Impairment Scale (AIS) A-D were included in the study.
The local committee of ethics approved the study protocol according to the Helsinki declaration, and all of the patients gave their written informed consent before the start of the study.
Procedure
During a 4-year period from November 2004 to November 2008, patients were admitted at the Spinal Cord Unit at the Viborg Regional Hospital. Blood samples were drawn to analyse serum CysC and creatinine levels. A 24-h urine was collected for the determination of creatinine clearance. 51 Cr-EDTA clearance was measured at the Department of Clinical Physiology.
Analytical methods
The blood samples were centrifuged at 2000 g for 12 min. Serum was isolated and analysed on the same day. The serum CysC levels were analysed using the Siemens N Latex CysC assay on the Dade Behring Nephelometer II (Siemens Diagnostics, Marburg, Germany). 11 The method was a fully automated particle-enhanced nephelometric immunoassay. The serum and urine creatinine levels were analysed by an enzymatic method traceable to the IDMS creatinine reference method on Modular P (Roche Diagnostics, Mannheim, Germany).
GFR was measured using a single injection technique with a 51 Cr-EDTA complex by a multiple plasma sample method. 12 The estimated GFR MDRD was calculated using the equation developed from the MDRD study. 8 Creatinine clearance and 51 Cr-EDTA clearance was adjusted to a body surface area of 1.73 m 2 .
GFR prediction model based on serum CysC
Initially, linear stepwise regression was used to test the relationship between the measured GFR and the independent variables of the serum CysC level, serum creatinine level, sex, age, height, weight, body surface area, and body mass index. This analysis indicated that the measured GFR was dependent on only the serum CysC value and was independent of the other variables tested in the study. For this reason, only models that included the variable serum CysC levels were tested.
Based on the hypothesis that GFR values can be calculated from the CysC values by the equation eGFR CysC ¼ A Â exp( Àk*CysC), the constants A and k were determined as those values, which made the sum over all measured values
as small as possible.
This method is superior to the ordinary exponential regression using weighted regression.
Statistical analysis
The statistical analysis was performed using the Student Edition of statistic version 2.0 (Analytical Software, Tallahassee, FL, USA), GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA), and Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Data are expressed as mean values ± s.d. A P-valueo0.05 was considered significant. ROC plots were constructed using GraphPad Prism and GraphROC for Windows version 2.0.
RESULTS

The study population
The characteristics of the study population are shown in Table 1 . Each value is reported as the mean ± s.d. The patients' characteristics according to the AIS impairment scale are shown in Table 2 . Thirtynine per cent of the patients (57 patients) with SCIs were complete Estimating GFR using serum cystatin C EJ Erlandsen et al
injuries (AIS A) and 61 per cent (88 patients) were incomplete injuries (AIS B-D).
Relationship between 51 Cr-EDTA clearance (GFR), CysC levels, creatinine levels, creatinine clearance and eGFR MDRD Figure 1 illustrates the relationship between 51 Cr-EDTA clearance, CysC levels, creatinine levels, creatinine clearance and eGFR MDRD 13 The upper reference interval for CysC levels is indicated by a solid horizontal line at 1.02 mg l À1 in Figure 1a and b. 14 The upper reference intervals for creatinine levels are indicated in Figure 1c and d by a solid horizontal line for men at 105 mmol l À1 and a dotted horizontal line for women at 90 mmol l À1 . 15 For creatinine clearance Estimating GFR using serum cystatin C EJ Erlandsen et al (Figure 1e and f) and for estimated GFR (Figure 1g and h), the upper reference intervals are indicated by a horizontal line at 90 ml min À1 per 1.73 m 2 . Table 4 shows the area under the curve (AUC) of the nonparametric ROC plots for the serum CysC levels, serum creatinine levels, creatinine clearance, eGFR MDRD and eGFR CysC using a GFR cutoff value of 90 ml min À1 per 1.73 m 2 . A comparison of the AUC for serum CysC levels with the AUC for serum creatinine levels as well as a comparison with the AUC for estimated GFR MDRD revealed a significant difference (P-valueo0.05) for all patients with SCIs (n ¼ 145), for patients with complete SCIs (n ¼ 57) and for patients with incomplete SCIs (n ¼ 88). There was no significant difference between the AUC for serum CysC levels and eGFR CysC compared with the AUC for creatinine clearance.
GFR prediction model based on serum CysC
The estimated GFR CysC (ml min À1 per 1.73 m 2 ) can be calculated from the serum CysC values (mg l À1 ) using the equation eGFR CysC ¼ 212 Á exp ( À0.914 Á CyC), an equation that was determined using the data from patients with complete and incomplete SCIs as shown in Table 5 . The corresponding equations for patients with complete and incomplete SCIs are also shown in Table 5 . The curves for the prediction models are shown in Figure 2a -c. The difference plot of the measured GFRs versus the difference between the measured GFR minus the eGFR CysC are shown in Figure 2d -f. The model was accurate within ±50% of the reference method in 98% of patients, accurate within ±30% of the reference method in 88% of patients, and accurate within ± 10% of the reference method in 50% of patients, as shown in Table 5 . In comparison, the eGFR MDRD model was accurate within ±50 of the reference method in 73% of patients, accurate within ±30% of the reference method in 52% of the patients and accurate within ± 10% of the reference method in 17% of the patients, as shown in Table 5 .
DISCUSSION
The present study including 145 patients is the first large cohort study comparing CysC levels with the 51 Cr-EDTA clearance, creatinine levels, creatinine clearance and estimated GFR MDRD in patients with complete and incomplete SCIs.
The findings in the present study suggest that serum CysC levels are a better index of the renal function than serum creatinine levels or eGFR MDRD in patients with complete and incomplete SCIs. No significant difference was found between serum CysC levels and creatinine clearance. Furthermore, this study showed that GFR can be estimated by a simple equation based on a single serum CysC value.
We have previously described a prospective study enroling 31 patients with spinal cord injuries and demonstrating that CysC levels correlated better with 51 Cr-EDTA clearance (GFR) than did serum creatinine levels and eGFR MDRD . 16 In 23 of the 31 patients, the creatinine clearance was determined, and no significant difference was found between CysC levels and creatinine clearance using non-parametric ROC plots. 16 In the present study, only three serum creatinine values exceeded the upper reference limit for serum creatinine, and eGFR MDRD overestimated the GFR by 37%. This finding is consistent with previous studies that also found that serum creatinine levels were not able to detect the early deterioration of renal function 1, 16 and that the eGFR MDRD equation, 5, 16, 17 the Cockcroft-Gault equation 1, 5, 16 and the CKD-EPI equation 17 overestimated the true creatinine clearance and the measured GFR. An empirically derived correction factor of 0.7 for the eGFR MDRD equation and 0.8 for the Cockcroft-Gault equation markedly improved the performance and accuracy of both formulas. 5 A 24-h creatinine clearance measured from collected urine was an acceptable method for measuring GFR in patients with SCIs. 1, 5, 16 In contrast to this finding, Sepahpanah et al. 6 reported significant variation in the serial testing of creatinine clearance and concluded that the test had little value as a screening test for renal disease in patients with SCIs. In the present study, we have developed separate equations for estimating GFR in patients with complete SCIs, incomplete SCIs and for both groups based on a single serum CysC value as shown in Table 5 . The equations are independent of sex, age and muscle mass. The differences between the three equations are slight, and we recommend using the equation developed for the whole group of patients with SCIs. As shown in the difference plot in Figure 2 , the difference between the measured and the eGFR CysC varies closely around zero and is independent of measured GFR.
The advantage of this equation is that it gives the estimated values for GFR whether CysC is below the reference range (o0.51 mg l À1 ) or close to the border of dialysis (4-5 mg l À1 ), unlike several published formulas for estimating GFR based on CysC levels. 18, 19 Over the last decade, only a few papers have described measuring and estimating the GFR in patients with SCIs. Creatinine levels or creatinine clearance were included in six papers, 1, 5, 6, 16, 17, 20 and CysC levels were included in only two papers. 16, 20 A gold standard for GFR, 99m Tc-DTPA clearance 1 or 51 Cr-EDTA clearance 16 was used in only two of the six studies.
The total number of patients with SCIs included in each of the six studies was relatively small: 36, 70, 116, 31, 27 and 141 patients. 1, 5, 16, 17, 20 In three of the studies, nearly 100% of the patients were men 5, 6, 17 and only 22 women (5%) out of 421 patients were included in the six studies. In the present study, 32% of the patients were women, which is more representative of the population with SCIs.
One limitation to the present study was the relatively low number of patients (11.7%) with a measured GFR o60 ml min À1 per 1.73 m 2 . Future research in this area should include a larger population of SCI patients with measured GFRs o60 ml min À1 1.73 m 2 to validate the new equation for eGFR CysC .
CONCLUSION
After comparing all of the variables examined in this study, serum CysC levels are a better index of GFRs than creatinine levels or eGFR MDRD . In patients with SCIs, GFRs can be estimated independent of age, sex and muscle mass using a single serum CysC value. Serum levels of creatinine and eGFR MDRD can not be used to detect early decrease of renal function. Creatinine clearance determinations can be used, but such methods are often difficult and time consuming for patients to perform. 
